Loading company
Xencor Inc
XNCR · Nasdaq · ·
Next earnings: November 4, 2026
$24.99-2.4%Sep 29 close
- 1M
- -10.5%
- 6M
- +99.4%
- 1Y
- +111.2%
- 5Y
- -28.5%
XNCR · Nasdaq · ·
Next earnings: November 4, 2026
$24.99-2.4%Sep 29 close
Xencor Inc is scheduled to report next on November 4, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $51.2M | $43.6M | +17.46% |
| Profit | -$21.7M | -$30.8M | +29.51% |
| Profit per share | -$0.29 | -$0.41 | +29.27% |
| Free Cash Flow | -$56.2M | -$36.8M | -52.91% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“We are excited to present XmAb819 results at ESMO this fall and for other fast-approaching key milestones across our wholly owned clinical pipeline,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of patients with cancer and autoimmune diseases. More than 20 candidates engineered with Xencor's XmAb ® technology are in clinical development, and multiple XmAb medicines are marketed by partners. Xencor’s XmAb engineering technology enables small changes to a protein’s structure that result in new mechanisms of therapeutic action.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Xencor Inc’s Item 2.02 8-K filed August 5, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Xencor Inc has no earnings call transcript available.